Passage Bio, Inc. (PASG)

Passage Bio's stock has been impacted by several events. The company announced a 1-for-20 reverse stock split on July 10, 2025. The company reported its Q2 2025 financial results and provided business highlights on August 12, 2025. Passage Bio participated in several investor conferences. The company reported its Q3 2025 financial results on November 10, 2025, reporting an EPS of -$2.44, which beat analysts' consensus estimates. The company reported updated interim data from its upliFT-D study in FTD-GRN on June 23, 2025, and announced interim data from the same study on January 10, 2025, showing PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL. The stock price as of January 8, 2026, was $18.33 per share, representing a 36.79% increase from January 10, 2025, with a 211.48% increase over the past six months.

Based on available data, there is no clear or reliable demand seasonality for Passage Bio, Inc.'s products and services due to insufficient stock data and poor correlation with the Healthcare sector's seasonal strength. As a clinical-stage company, revenue is primarily from equity financing and collaborations, not product sales, so traditional demand seasonality does not apply.

Passage Bio, Inc. (PASG) is a clinical-stage genetic medicines company focused on developing therapies for rare, monogenic central nervous system (CNS) diseases, operating within the Healthcare sector and Biotechnology industry. Passage Bio leverages a proprietary adeno-associated virus (AAV) gene therapy platform to deliver gene therapies. Its major product candidates include PBGM01 for infantile GM1 gangliosidosis, PBFT02 for frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN) and being explored for ALS and Alzheimer's, PBKR03 for infantile Krabbe disease, PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and a preclinical research program for Huntington's disease.

Passage Bio, Inc. is headquartered in Philadelphia, Pennsylvania, United States, and maintains a manufacturing and global clinical distribution center in Hopewell, New Jersey.

Passage Bio's brand reputation, as reflected by analyst sentiment, appears generally positive, receiving a consensus rating of "Moderate Buy" or "Strong Buy". A strategic restructuring in early 2025 involved out-licensing pediatric programs, a 55% workforce reduction, and cessation of internal lab operations to focus on PBFT02 for frontotemporal dementia (FTD) and improve operational efficiency.

Passage Bio, Inc. has significant institutional ownership, with approximately 51.87% to 53.48% of its stock held by institutions including Lynx1 Capital Management LP, Vestal Point Capital, LP, and others. Insider ownership is around 4.30%. Orbimed Advisors LLC is a significant individual shareholder, owning 12.01 million shares.